VIRBAC CORPORATION NAMES COURTNEY CARNEY DIRECTOR OF MARKETING, PARASITICIDES

Fort Worth, Texas (June 12, 2015) – Virbac Corporation today announced that Mrs. Courtney Carney has been named Director of Marketing, Parasiticides. In this new role, Mrs. Carney will be responsible for planning, directing and providing market leadership for Virbac's extensive parasiticide franchise in the U.S.

Robert Daily, Vice President of Marketing said "Courtney's experience makes her an immediate asset to the marketing organization, but she will also be a valuable contributor to the overall sales and business strategy of Virbac as we continue to grow."

Mrs. Carney brings over 15 years of animal health experience in diverse roles such as marketing, sales and commercial operations. Her background includes brand management, sales leadership, marketing analytics and product stewardship at Novartis Animal Health. Most recently, she served as the Associate Director of Marketing, Parasiticides at Merck Animal Health.

Courtney received her Bachelor of Science degree in Business and Economics from Greensboro College and her MBA from Capella University. She and her family will relocate to Fort Worth in the near future.

One of the world's largest laboratories dedicated exclusively to animal health, Virbac develops, manufactures, and distributes a wide range of products and services intended for the prevention and treatment of common pathologies in companion animals. Virbac Corporation, located in Fort Worth, Texas, is a leading companion animal health company offering products in the heartworm, tick and flea, dermatology, antibiotic, endocrinology, senior care, behavior, critical care nutrition, and oral hygiene markets. Virbac products are available to pet owners exclusively through a veterinarian.

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…